P2RY1 and neoplasm: Simulation experiments with baseline platelets resulted in 95 ± 5% tumor adhesion vs. 5.5 ± 7% (p < 0.001) with thromboxane inhibition, 32 ± 26% (p < 0.05) with ADP receptor inhibition and 4 ± 5% (p < 0.001) with combined inhibition.